STRUCTURE AND TRAFFICKING OF PCSK9 IN LDL BINDING

被引：0
作者：
Matteucci, Sara [1 ]
Pravata, Valentina [1 ]
Esposito, Francesco Maria [1 ]
Arnaboldi, Lorenzo [2 ]
Gianazza, Erica [3 ]
Grigore, Liliana [1 ]
Banfi, Cristina [3 ]
Catapano, Alberico [1 ]
机构：
[1] IRCCS Multimed, Milan, Italy
[2] Univ Milan, Dept Pharmacol Sci Rodolfo Paoletti Disfeb, Milan, Italy
[3] IRCCS Monzino Cardiol Ctr, Milan, Italy
来源：
ATHEROSCLEROSIS | 2024年 / 395卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P220
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    Milazzo, Laura
    Antinori, Spinello
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (25) : 2425 - 2425
  • [22] Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction
    Tavori, Hagai
    Melone, Michelle
    Rashid, Shirya
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2014, 12 (10) : 1137 - 1144
  • [23] Beyond LDL Cholesterol, a New Role for PCSK9
    Akram, Omar N.
    Bernier, Adeline
    Petrides, Francine
    Wong, Gida
    Lambert, Gilles
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (07) : 1279 - 1281
  • [24] An Allosteric Binding Site on Sortilin Regulates the Trafficking of VLDL, PCSK9, and LDLR in Hepatocytes
    Sparks, Robert P.
    Arango, Andres S.
    Jenkins, Jermaine L.
    Guida, Wayne C.
    Tajkhorshid, Emad
    Sparks, Charles E.
    Sparks, Janet D.
    Fratti, Rutilio A.
    [J]. BIOCHEMISTRY, 2020, 59 (45) : 4321 - 4335
  • [25] PCSK9 MUTATIONS: EFFECTS BEYOND LDL CHOLESTEROL
    Zampoleri, V.
    Casula, M.
    Gazzotti, M.
    Baragetti, A.
    Pellegatta, F.
    Grigore, L.
    Catapano, A. L.
    [J]. ATHEROSCLEROSIS, 2019, 287 : E195 - E196
  • [26] PCSK9 and atherosclerosis: Looking beyond LDL regulation
    Ragusa, Rosetta
    Basta, Giuseppina
    Neglia, Danilo
    De Caterina, Raffaele
    Del Turco, Serena
    Caselli, Chiara
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2021, 51 (04)
  • [27] Identification of amino acid residues in the ligand binding repeats of LDL receptor important for PCSK9 binding
    Deng, Shi-jun
    Alabi, Adekunle
    Gu, Hong-mei
    Adijiang, Ayinuer
    Qin, Shucun
    Zhang, Da-wei
    [J]. JOURNAL OF LIPID RESEARCH, 2019, 60 (03) : 516 - 527
  • [28] Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1
    Shiori Sato
    Yumiko Akamine
    Hideaki Kagaya
    Mitsuru Saito
    Takamitsu Inoue
    Kazuyuki Numakura
    Tomonori Habuchi
    Shigeru Satoh
    Masatomo Miura
    [J]. Pharmacological Reports, 2020, 72 : 622 - 630
  • [29] Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification
    Tveten, Kristian
    Holla, Oystein L.
    Cameron, Jamie
    Strom, Thea Bismo
    Berge, Knut Erik
    Laerdahl, Jon K.
    Leren, Trond P.
    [J]. HUMAN MOLECULAR GENETICS, 2012, 21 (06) : 1402 - 1409
  • [30] Changes in PCSK9 and LDL cholesterol concentrations by everolimus treatment and their effects on polymorphisms in PCSK9 and mTORC1
    Sato, Shiori
    Akamine, Yumiko
    Kagaya, Hideaki
    Saito, Mitsuru
    Inoue, Takamitsu
    Numakura, Kazuyuki
    Habuchi, Tomonori
    Satoh, Shigeru
    Miura, Masatomo
    [J]. PHARMACOLOGICAL REPORTS, 2020, 72 (03) : 622 - 630
12345